Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)

Eric R. Marcotte, Anita Chugh, Ram K. Mishra, Rodney L. Johnson

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

3(R)-[(2(S)-Pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) is a peptidomimetic analog of Pro-Leu-Gly-NH2 (PLG or MIF-1) that has previously been demonstrated to be more potent and efficacious that MIF- 1 in enhancing dopamine receptor activity. Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model. PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Whether the enhanced neuroprotective effect of PAOPA is due to dopamine receptor stimulation, or a result of reduced oxidative stress through normalization of dopamine turnover, remains to be determined.

Original languageEnglish (US)
Pages (from-to)403-406
Number of pages4
JournalPeptides
Volume19
Issue number2
DOIs
StatePublished - Feb 1 1998

Fingerprint Dive into the research topics of 'Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH<sub>2</sub> (PLG, MIF-1)'. Together they form a unique fingerprint.

  • Cite this

    Marcotte, E. R., Chugh, A., Mishra, R. K., & Johnson, R. L. (1998). Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1). Peptides, 19(2), 403-406. https://doi.org/10.1016/S0196-9781(97)00321-5